Nuclear Medicine and Biology
Volume 38, Issue 1 , Pages 129-136 , January 2011

A kit to prepare 111In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer

  • Deborah A. Scollard

      Affiliations

    • Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada M5S 3M2
    • ,
  • Conrad Chan

      Affiliations

    • Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada M5S 3M2
    • ,
  • Claire M.B. Holloway

      Affiliations

    • Department of Surgery, Sunnybrook Health Sciences Centre, Toronto, ON, Canada M4N 1H1
    • ,
  • Raymond M. Reilly

      Affiliations

    • Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada M5S 3M2
    • Department of Medical Imaging, University of Toronto, Toronto, ON, Canada M5S 3E2
    • Toronto General Research Institute, University Health Network, Toronto, ON, Canada M5G 2M9
    • Corresponding Author InformationCorresponding author. Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada M5S 3M2. Tel.: +1 416 946 5522; fax: +1 416 978 8511.

Received 9 January 2010 ,Revised 2 June 2010 ,Accepted 30 June 2010.

References 

  1. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer. 1998;34:791–808
  2. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992;23:974–979
  3. Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat. 1998;52:65–77
  4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  5. McLarty K, Reilly RM. Molecular imaging as a tool for personalized and targeted anticancer therapy. Clin Pharmacol Ther. 2007;81:420–424
  6. Reilly RM. Aiming for a direct hit: combining molecular imaging with targeted cancer therapy. J Nucl Med. 2009;50:1017–1019
  7. Badellino F, Bertoglio S, Mariani G, Meszaros P, Canavese G, Percivale P. Use of radioimmunoguided surgery after induction chemotherapy in locally advanced breast cancer. Semin Surg Oncol. 1998;15:245–248
  8. Percivale P, Bertoglio S, Meszaros P, Canavese G, Cafiero F, Gipponi M, et al. Radioimmunoguided surgery after primary treatment of locally advanced breast cancer. J Clin Oncol. 1996;14:1599–1603
  9. Behr TM, Béhé M, Wörmann B. Trastuzumab and breast cancer. N Engl J Med. 2001;345:995–996
  10. McLarty K, Cornelissen B, Cai Z, Scollard D, Costantini D, Done SJ, et al. 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing human breast cancer xenografts. J Nucl Med. 2009;50:1340–1348
  11. McLarty K, Cornelissen B, Scollard DA, Done SJ, Chun K, Reilly RM. Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging. 2009;36:81–93
  12. Perik PJ, Lub-de Hooge MN, Gietema JA, van der Graaf WTA, de Korte MA, Jonkman S, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24:2276–2282
  13. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER-2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004;22:704–706
  14. Tang Y, Wang J, Scollard DA, Mondal H, Holloway C, Kahn HJ, et al. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol. 2005;32:51–58
  15. Tang Y, Scollard D, Chen P, Wang J, Holloway C, Reilly RM. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [99mTc]-HYNIC-trastuzumab (Herceptin) Fab fragments. Nucl Med Commun. 2005;26:427–432
  16. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, et al. Increased affinity leads to improved selective tumour delivery of single-chain Fv antibodies. Cancer Res. 1998;58:485–490
  17. Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 2005;65:1471–1478
  18. Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ, et al. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res. 2005;65:5907–5916
  19. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Design. 2008;14:2999–3019
  20. Kramer-Marek G, Kiesewetter DO, Capala J. HER2 expression changes in breast cancer xenografts following therapeutic intervention can be quantified using PET imaging and 18F-labeled affibody molecules. J Nucl Med. 2009;50:1131–1139
  21. Orlova A, Wållberg H, Stone-Elander S, Tolmachev V. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med. 2009;50:417–425
  22. Reilly RM, Sandhu J, Alvarez-Diez TM, Gallinger S, Kirsh J, Stern H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet. 1995;28:126–142
  23. Reilly RM, Scollard DA, Wang J, Mondal H, Chen P, Henderson LA, et al. A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications. J Nucl Med. 2004;45:701–708
  24. Anonymous . Octreoscan Kit for the preparation of indium-111 pentetreotide. St. Louis (Mo): Mallinckrodt Medical Inc; 1995;
  25. Anonymous . Questions and answers about FDA's enforcement action regarding unapproved topical drug products containing papain. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/ucm119646.htmAccessed January 9, 2010
  26. Reilly RM. The radiopharmaceutical science of monoclonal antibodies and peptides for imaging and targeted in situ radiotherapy of malignancies. In:  Gad SC editors. Handbook of Biopharmaceutical Technology. Toronto: John Wiley & Sons; 2007;p. 987–1053

☆ This study was supported by grants to C.H. (No. 05NOV00176) and R.M.R. (1 mm Challenge) from the Ontario Institute of Cancer Research with funds from the Province of Ontario.

PII: S0969-8051(10)00323-9

doi: 10.1016/j.nucmedbio.2010.06.010

Nuclear Medicine and Biology
Volume 38, Issue 1 , Pages 129-136 , January 2011

Article Tools

* Image Usage & Resolution